HepG2 Attenuation Induced by RNase A Modulates Gene Profiling and Immunophenotypic Characterization of Some Immune Cells Operating in Cancer Vaccine
| Autor: | Mahmoud Singer, Fatma F. Abdel Hamid, Mahmoud N El-Rouby, Mahmoud M. Said, Motawa E. El-Houseini, Reda Tabashy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
biology RNase P medicine.medical_treatment CD44 Antigen presentation Immunotherapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Immune system Antigen 030220 oncology & carcinogenesis medicine Cancer research biology.protein Cytotoxic T cell Cancer vaccine |
| Zdroj: | Journal of Cancer Research Updates. 7:27-34 |
| ISSN: | 1929-2279 |
| DOI: | 10.6000/1929-2279.2018.07.01.3 |
| Popis: | Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer death. Attempts to induce an effective immune response against cancer by immunotherapeutic intervention, including activation of dendritic cells (DCs), were established. The present study was undertaken to investigate the attenuation of HepG2 cells using ribonuclease enzyme A (RNase A) as a possible biological factor to sensitize allogenic DCs and lymphocytes isolated from Egyptian HCC patients. Attenuation of HepG2 cells resulted in a significant increase in activated DC and T-lymphocyte markers, upregulation of CD44 gene expression and increased lactate dehydrogenase as well as interleukin-12 levels. In contrast, a significant decrease in mature DCs, B-cells, T-helper, cytotoxic T-cells, and NK-cells, as well as LMP-2 gene expression was recorded. In conclusion, the attenuation of HepG2 cells with RNase A and subsequent pulsation to allogenic DCs and lymphocytes caused a differential immune response. Further studies are recommended to explain the role of RNase A in modulating antigen expression on the tumor cell surface. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|